What are the adult hypertension stages and their recommended management?

Hypertension Staging and Management

Adult hypertension is classified into four stages based on blood pressure measurements, with Stage 2 hypertension (≥140/90 mm Hg) requiring immediate initiation of dual-agent therapy, preferably as a single-pill combination, while Stage 1 hypertension (130-139/80-89 mm Hg) can be managed with monotherapy and sequential titration. 1, 2

Blood Pressure Classification

The current staging system defines:

• Normal BP: SBP <120 mm Hg AND DBP <80 mm Hg
• Elevated BP: SBP 120-129 mm Hg AND DBP <80 mm Hg
• Stage 1 Hypertension: SBP 130-139 mm Hg OR DBP 80-89 mm Hg
• Stage 2 Hypertension: SBP ≥140 mm Hg OR DBP ≥90 mm Hg

1, 2

Management Algorithm by Stage

Stage 2 Hypertension (≥140/90 mm Hg)

Initiate combination therapy with 2 first-line agents from different classes, ideally as a single-pill combination (Class 1, Level B-R). 1, 2 This approach is superior because:

• Most patients require ≥2 medications to achieve BP control
• Single-pill combinations improve adherence rates significantly
• Combining complementary mechanisms enhances BP lowering while reducing side effects (e.g., ACEi/ARB + thiazide reduces electrolyte disturbances; ACEi/ARB + CCB reduces leg edema)
• Observational data shows fewer cardiovascular events and deaths with single-pill combinations versus multiple separate pills 2

First-line drug classes (choose 2 from different classes):

• Thiazide-type diuretics
• Long-acting dihydropyridine calcium channel blockers (CCB)
• ACE inhibitors (ACEi)
• Angiotensin receptor blockers (ARB)

1, 2

Stage 1 Hypertension (130-139/80-89 mm Hg)

Start with a single first-line antihypertensive agent, then titrate dose and sequentially add agents as needed (Class 2a, Level C-EO). 1, 2 This stepped-care approach is reasonable for Stage 1, particularly when:

• Initial BP is close to target
• Patient is older or frail
• History of hypotension or multiple drug side effects exists

However, consider initial dual therapy even in Stage 1 for high-risk patients including:

• Non-Hispanic Black adults
• ASCVD risk >7.5%
• BP ≥20/10 mm Hg above target

2

Elevated BP (120-129/<80 mm Hg)

Focus on lifestyle interventions without pharmacotherapy. This includes:

• DASH diet
• Dietary sodium restriction
• Potassium enrichment
• Regular exercise
• Weight loss
• Alcohol moderation

3

Critical Contraindications

Never combine ACEi + ARB + renin inhibitor simultaneously (Class 3: Harm, Level A). 1, 2 This triple RAS blockade increases risk of:

• Cardiovascular disease
• Kidney disease progression
• Hyperkalemia

2

Additional combinations to avoid:

• Two drugs from the same class (except thiazide + potassium-sparing diuretics, or thiazide + loop diuretics)
• Dual RAS blockade (ACEi + ARB, or either with aliskiren)

Adherence Optimization Strategies

Use once-daily dosing and single-pill combinations (both Class 1, Level B-R) to maximize adherence. 2 Single-pill combinations reduce pill burden and are more cost-effective than multiple separate pills while improving BP control rates.

Common Pitfalls

1. Undertreatment of Stage 2: Starting monotherapy when dual therapy is indicated delays BP control and increases cardiovascular risk
2. Inadequate follow-up intervals: Longer intervals in stepped-care approaches extend time to BP goal
3. Ignoring high-risk Stage 1 patients: Black adults and those with high ASCVD risk benefit from more aggressive initial therapy
4. Overly cautious in older adults: While monitoring for hypotension is important, undertreating hypertension increases mortality risk—carefully initiate and monitor rather than withhold treatment 2